This site is intended for US residents only.

  • Important Safety Information
  • Prescribing Information
  • Patient Information
  • Healthcare Professional Site

    • This site is intended for US healthcare professionals only.

    JIDEYTRO (zidesamtinib) 25 mg and 100 mg tablets
    Stay connected

    NOW APPROVED

    Icon

    Patient8 portrayal.

    Everyday moments AND ROS1+ lung cancer CAN COEXIST

    Learn about JIDEYTRO

    Patient portrayal.

    JIDEYTRO is a new treatment for adults with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC) who received a prior ROS1-targeted therapy

    JIDEYTRO

    (pronounced jih-DAY-troh)

    What would treatment on your terms look like?

    1

    The potential for long-lasting results* for pretreated people

    2

    May help after other treatments stop working

    3

    Tolerability that may help you stay on therapy

    *"Long-lasting results" is based on the overall response rate and the 12-month duration of response rate in the full study population.

    Results with JIDEYTRO

    The clinical study looked at how JIDEYTRO may help people with advanced ROS1+ NSCLC who had different prior treatments

    See the results

    Taking JIDEYTRO

    JIDEYTRO offers once-daily dosing and may be taken with or without food.

    Learn more
    Jideytro (zidesamtinib) 100 mg tablets shown in a prescription bottle and carton, with one tablet in front

    Questions about financial assistance?

    Find information to help you navigate your insurance coverage and the cost of medication.

    Learn more

    Download JIDEYTRO resources

    Explore educational resources as you
    consider next steps.

    Visit the library

    ROS1+=ROS proto-oncogene 1-positive.